| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RVNC | Common Stock | Award | $0 | +122K | +14.53% | $0.00 | 963K | Aug 11, 2023 | Direct | F1 |
| transaction | RVNC | Common Stock | Tax liability | -$909K | -48.1K | -4.99% | $18.91 | 914K | Aug 11, 2023 | Direct | F2 |
| holding | RVNC | Common Stock | 111K | Aug 11, 2023 | See footnote | F3 |
| Id | Content |
|---|---|
| F1 | Represents the vesting of a performance-based restricted stock award (PSA) granted on February 2, 2021. On August 11, 2023, the Issuer's Compensation Committee certified 100% of the PSAs eligible to vest based on (i) the achievement of a cumulative revenue goal, calculated in accordance with GAAP, adjusted to exclude revenue recognized from collaboration agreements and classified as collaboration revenue, measured beginning on January 1, 2021, provided the goal is achieved on or before the three-year anniversary of the U.S. Food and Drug Administration's approval of the Issuer's biologics license application for DAXXIFY(R) for the improvement of glabellar lines, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date. |
| F2 | Represents the number of shares withheld by and surrendered to the Issuer on August 11, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the PSA. |
| F3 | These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002. |